GLUE Insider Trading Activity and SEC Form 4 Filings
GLUE insider trading summary
Over the past 12 months, insiders at Monte Rosa Therapeutics, Inc. (GLUE) reported 29 sales worth $2.5M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.5M.
Latest GLUE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Matthew Bowen | Principal Accounting Officer | Sell | $137 (13 @ $10.56) |
| Jul 16, 2026 | Markus Warmuth | President & CEO | Sell | $220K (9,500 @ $23.18) |
| Jul 15, 2026 | Jennifer Champoux | Chief Operating Officer | Sell | $102K (4,351 @ $23.38) |
| Jul 6, 2026 | Sharon Townson | Chief Scientific Officer | Sell | $10K (400 @ $24.13) |
| Jul 6, 2026 | Sharon Townson | Chief Scientific Officer | Sell | $130K (5,600 @ $23.25) |
| Jun 30, 2026 | Filip Janku | Chief Medical Officer | Sell | $132K (5,407 @ $24.50) |
| Jun 17, 2026 | Jennifer Champoux | Chief Operating Officer | Sell | $41K (2,176 @ $19.00) |
| Jun 17, 2026 | Sharon Townson | Chief Scientific Officer | Sell | $57K (3,000 @ $19.00) |
| Jun 1, 2026 | Markus Warmuth | President & CEO | Sell | $97K (4,998 @ $19.41) |
| Jun 1, 2026 | Markus Warmuth | President & CEO | Sell | $9K (468 @ $19.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.